| Galectins and Cancer Biology | Lifetime | 10 | NL 1 | 99.67 |
| Cardiovascular Function and Risk Factors | Lifetime | 88 | NL 4 | 99.82 |
| Heart Failure Treatment and Management | Lifetime | 51 | NL 4 | 99.78 |
| Chemotherapy-induced cardiotoxicity and mitigation | Lifetime | 15 | NL 1 | 99.24 |
| GDF15 and Related Biomarkers | Lifetime | 7 | NL 1 | 99.13 |
| Peptidase Inhibition and Analysis | Lifetime | 109 | NL 2 | 99.46 |
| Diabetes Treatment and Management | Lifetime | 111 | NL 3 | 99.49 |
| Signaling Pathways in Disease | Lifetime | 53 | NL 1 | 99.16 |
| Cardiac Fibrosis and Remodeling | Lifetime | 40 | NL 2 | 99.15 |
| Macrophage Migration Inhibitory Factor | Lifetime | 38 | NL 1 | 97.93 |
| Cardiomyopathy and Myosin Studies | Lifetime | 365 | NL 15 | 97.94 |
| Potassium and Related Disorders | Lifetime | 107 | NL 7 | 97.66 |
| Cardiac Structural Anomalies and Repair | Lifetime | 787 | NL 24 | 97.89 |
| Viral Infections and Immunology Research | Lifetime | 682 | NL 24 | 96.82 |
| Cardiac pacing and defibrillation studies | Lifetime | 857 | NL 43 | 97.58 |
| Cardiovascular Effects of Exercise | Lifetime | 970 | NL 40 | 95.30 |
| Erythropoietin and Anemia Treatment | Lifetime | 392 | NL 12 | 94.52 |
| Cardiovascular, Neuropeptides, and Oxidative Stress Research | Lifetime | 945 | NL 7 | 85.69 |
| Heart rate and cardiovascular health | Lifetime | 926 | NL 37 | 62.63 |
| Cardiovascular Function and Risk Factors | 2021-2025 | 14 | NL 1 | 99.89 |
| Heart Failure Treatment and Management | 2021-2025 | 25 | NL 1 | 99.82 |
| Cardiomyopathy and Myosin Studies | 2021-2025 | 22 | NL 3 | 99.06 |
| Cardiac Fibrosis and Remodeling | 2021-2025 | 8 | NL 1 | 97.97 |
| Chemotherapy-induced cardiotoxicity and mitigation | 2021-2025 | 19 | NL 1 | 98.28 |
| Diabetes Treatment and Management | 2021-2025 | 127 | NL 4 | 98.58 |
| Cardiovascular Disease and Adiposity | 2021-2025 | 76 | NL 3 | 95.98 |
| GDF15 and Related Biomarkers | 2021-2025 | 11 | NL 2 | 94.65 |
| Metabolism, Diabetes, and Cancer | 2021-2025 | 105 | NL 2 | 96.32 |
| Viral Infections and Immunology Research | 2021-2025 | 131 | NL 3 | 94.29 |
| Cardiovascular Effects of Exercise | 2021-2025 | 132 | NL 6 | 96.24 |
| Cardiac pacing and defibrillation studies | 2021-2025 | 264 | NL 9 | 96.83 |
| Cardiac Structural Anomalies and Repair | 2021-2025 | 338 | NL 11 | 96.04 |
| Signaling Pathways in Disease | 2021-2025 | 34 | NL 1 | 89.52 |
| Pancreatic function and diabetes | 2021-2025 | 410 | NL 6 | 93.20 |
| Cardiac electrophysiology and arrhythmias | 2021-2025 | 467 | NL 29 | 94.10 |
| Congenital heart defects research | 2021-2025 | 251 | NL 20 | 86.56 |
| Cancer, Hypoxia, and Metabolism | 2021-2025 | 1,000 | NL 12 | 85.99 |
| Peptidase Inhibition and Analysis | 2021-2025 | 887 | NL 12 | 86.75 |
| Galectins and Cancer Biology | 2021-2025 | 248 | NL 11 | 83.07 |
| Potassium and Related Disorders | 2021-2025 | 153 | NL 9 | 87.10 |
| Macrophage Migration Inhibitory Factor | 2021-2025 | 112 | NL 6 | 71.29 |
| Cardiac tumors and thrombi | 2021-2025 | 848 | NL 31 | 68.69 |
| Cardiovascular, Neuropeptides, and Oxidative Stress Research | 2021-2025 | 339 | NL 8 | 58.19 |
